CDIM binding proteins and uses thereof

• US 9,409,976 B2
• Filed: 02/08/2013
• Issued: 08/09/2016
• Est. Priority Date: 02/08/2012
• Status: Active Grant

• Current Assignee: Mcure Biosciences Incorporated
• Original Assignee: IGM Biosciences, Inc.
• Inventors: Teng, Nelson N. H., Bhat, Neelima M., Bieber, Marcia M., Keyt, Bruce A.
• Primary Examiner(s): ROARK, JESSICA HOPE
• Application Number:
  US13/763,398
• Publication Number:
  US 20140044739A1
• Time in Patent Office: 1,278 Days
• US Class Current: 1/1
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/3061 Blood cells
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative- and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.

Claims

1. An isolated antibody or antigen-binding fragment thereof that binds to the linear B cell lactosamine antigen CDIM, comprising:

(a) a heavy chain comprising a CDRH1 having the sequence shown in SEQ ID NO;

76, a CDRH2 having the sequence shown in SEQ ID NO;

77, and a CDRH3 having the sequence shown in any one of SEQ ID NOS;

78-90, 92-98, or 99; and

(b) a light chain comprising (i) a CDRL1 having the sequence shown in SEQ ID NO;

100, a CDRL2 having the sequence shown in SEQ ID NO;

102 and a CDRL3 having the sequence shown in SEQ ID NO;

104, or (ii) a CDRL1 having the sequence shown in SEQ ID NO;

101, a CDRL2 having the sequence shown in SEQ ID NO;

103, and a CDRL3 having the sequence shown in SEQ ID NO;

105.

2. The isolated antibody or an antigen-binding fragment thereof of claim 1, which does not cross-react with single stranded DNA (ssDNA), double stranded DNA (dsDNA), lipopolysaccharide, cardiolipin, chondroitin, and heparan.

3. The isolated antibody or an antigen-binding fragment thereof of claim 1, further comprising:

a heavy chain comprising a framework 1 (FR1) shown in any of SEQ ID NOS;

1-22.

6. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, or a multi-specific antibody.

7. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein the antigen-binding fragment is a Fab fragment, a Fab′

fragment, a F(ab)2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

8. The isolated antibody or an antigen-binding fragment thereof of claim 6, wherein the antibody is a human antibody.

9. The isolated antibody or an antigen-binding fragment thereof of claim 6, wherein the antibody is a monoclonal antibody.

10. The isolated antibody or an antigen-binding fragment thereof of claim 6, wherein the antibody has an isotype selected from the group consisting of IgA, IgD, IgM, IgG, and IgE.

11. The isolated antibody or an antigen-binding fragment thereof of claim 10, wherein the antibody is an IgM.

12. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein said antibody or an antigen-binding fragment thereof is coupled to a labeling group.

13. The isolated antibody or an antigen-binding fragment thereof of claim 12, wherein said labeling group is a radioisotope, a radionuclide, a fluorescent group, an enzymatic group, a chemiluminescent group, a biotinyl group, or a predetermined polypeptide group.

14. The isolated antibody or an antigen-binding fragment thereof of claim 1, wherein said antibody or an antigen-binding fragment thereof is coupled to an effector group.

15. The isolated antibody or an antigen-binding fragment thereof claim 14, wherein said effector group is a radioisotope, a radionucleotide, a toxin, a therapeutic group, or a chemotherapeutic group.

16. The isolated antibody or an antigen-binding fragment thereof of claim 15, wherein the therapeutic or chemotherapeutic group is selected from the group consisting of calicheamicin, auristatin-PE, geldanamycin, and maytansine.

17. The isolated antibody or an antigen-binding fragment thereof of claim 6, wherein said antibody or an antigen-binding fragment thereof is characterized by (a) the presence of a J chain;

or (b) the absence of a J chain.

18. A mixture of the antibody or an antigen-binding fragment thereof according to claim 11, wherein said mixture is a mixture comprising pentamers and hexamers.

19. A pharmaceutical composition comprising as an active agent at least one antibody or an antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier, diluent or adjuvant.

20. A kit comprising the isolated antibody or an antigen-binding fragment thereof of claim 1.

21. The kit of claim 20, comprising a further therapeutic agent.

22. The kit of claim 21, wherein the further therapeutic agent is an antineoplastic agent.

23. The kit of claim 22, wherein the anti-neoplastic agent is an anti-tumor antibody or a chemotherapeutic agent.

4. An isolated antigen binding protein that binds to the linear B cell lactosamine antigen CDIM, comprising a heavy chain variable region sequence selected from the group consisting of SEQ ID NOS:

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, and 22, and a light chain variable region sequence selected from the group consisting of SEQ ID NOS;

23 and 24.

5. An isolated antigen binding protein that binds to the linear B cell lactosamine antigen CDIM, comprising:

(a) a heavy chain variable region selected from the group consisting of SEQ ID NO;

1, SEQ ID NO;

2, and SEQ ID NO;

12; and

(b) a light chain variable region selected from the group consisting of SEQ ID NO;

23 and SEQ ID NO;

24.